Noemi Mergen

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier et al. · Journal of Clinical Oncology · 2014 · 659 citations

Medicine, Hematology, Oncology +15

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia

Franco Locatelli, Gerhard Zugmaier, Carmelo Rizzari et al. · JAMA · 2021 · 325 citations · Full text

Medicine, Hematology, Pediatrics +17

Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia

Nicola Gökbuget, Gerhard Zugmaier, Hervé Dombret et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 87 citations · Full text

Medicine, Hematology, Oncology +17

Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis

Franco Locatelli, Gerhard Zugmaier, Noemi Mergen et al. · Blood Advances · 2022 · 69 citations · Full text

Medicine, Hematology, Oncology +17

Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Max S. Topp, Nicola Goekbuget, Gerhard Zugmaier et al. · Blood · 2012 · 43 citations

Medicine, Hematology, Oncology +16